A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.
Cibeira MT et al. Br J Haematol. 2015 May 14. doi: 10.1111/bjh.13500. [Epub ahead of print].
Bortezomib in type I cryoglobulinemic vasculitis: are we acting too late?
Ramirez GA et al. Intern Med. 2015;54(9):1119-23. doi: 10.2169/internalmedicine.54.3668. Epub 2015 May 1.
Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death.
Warsame R et al. Blood Cancer J. 2015 May 1;5:e310. doi: 10.1038/bcj.2015.34.
Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both.
Zand L et al. Leuk Lymphoma. 2015 May 12:1-8. [Epub ahead of print]